Search Result
Results for "
anticonvulsant effects
" in MedChemExpress (MCE) Product Catalog:
2
Biochemical Assay Reagents
20
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-P1932
-
-
-
- HY-Y1267
-
-
-
- HY-N6778
-
|
|
Potassium Channel
Calcium Channel
Reactive Oxygen Species (ROS)
|
Neurological Disease
|
|
Paxilline is an indole alkaloid mycotoxin derived from Penicillium paxilli, which effectively inhibits the BK channel through a channel-blocking mechanism. Paxilline also inhibits sarco/endoplasmic reticulum Ca 2+-stimulated ATPase (SERCA), with IC50 values ranging from 5 μM to 50 μM for different SERCA isoforms. Paxilline exhibits significant anticonvulsant and neuroprotective effects, as well as certain antioxidant activity .
|
-
-
- HY-12882A
-
|
NP-120 tartrate; RC-61-91 tartrate
|
iGluR
Adrenergic Receptor
Potassium Channel
Calcium Channel
Influenza Virus
|
Infection
Neurological Disease
|
|
Ifenprodil (NP-120) tartrate, a cerebral vasodilator, is a noncompetitive NMDA receptor antagonist. Ifenprodil tartrate exerts high affinity at NR1A/NR2B receptors (IC50=0.34 μM) over 400-fold than at NR1A/NR2A receptors (IC50=146 μM) . Ifenprodil tartrate is an α1 adrenergic receptor antagonist. Ifenprodil tartrate inhibits GIRK (Kir3), reduces inward currents through the basal GIRK activity. Ifenprodil tartrate has reliable inhibitory effects against A/H1N1 strains (EC50 of 6.6 µM). Ifenprodil tartrate has neuroprotective, anticonvulsant and antinociceptive effects. Ifenprodil tartrate can be used for the study of cerebrovascular diseases and peripheral arterial obliterative disease .
|
-
-
- HY-N1469
-
-
-
- HY-A0042
-
|
CGP 33101; E 2080; RUF 331
|
Sodium Channel
|
Neurological Disease
|
|
Rufinamide (CGP 33101) is an orally active antiepileptic compound that inhibits Na + current activation, inhibits neuronal hyperexcitability, and has anticonvulsant effects. Rufinamide is used in the study of Lennox-Gastaut syndrome .
|
-
-
- HY-B0114
-
|
GP 47680
|
Sodium Channel
Apoptosis
|
Neurological Disease
Cancer
|
|
Oxcarbazepine is a sodium channel blocker . Oxcarbazepine significantly inhibits glioblastoma cell growth and induces apoptosis or G2/M arrest in glioblastoma cell lines . Anti-cancer and anticonvulsant effects .
|
-
-
- HY-108964
-
-
-
- HY-B1229
-
|
3-Methylbutanamide
|
GABA Receptor
|
Neurological Disease
Metabolic Disease
|
|
Isovaleramide (3-Methylbutanamide) is an orally active anticonvulsant. Isovaleramide inhibits alcohol dehydrogenase (ADH) activity and regulates GABAergic system. Isovaleramide reduces acute kidney injury. Isovaleramide has antiepileptic, anxiolytic, sedative and hypnotic effects[1] .
|
-
-
- HY-A0092
-
|
3,5,5,-Trimethyloxazolidine-2,4-dione
|
Calcium Channel
|
Neurological Disease
|
|
Trimethadione (3,5,5,-Trimethyloxazolidine-2,4-dione) is an oxazolidinedione anticonvulsant agent widely used against absences seizures. Trimethadione also is a T-type calcium channel blocker which has antihyperalgesic effects .
|
-
-
- HY-P1334
-
-
-
- HY-12882
-
|
NP-120; RC-61-91
|
iGluR
Adrenergic Receptor
Potassium Channel
Calcium Channel
Influenza Virus
|
Infection
Neurological Disease
|
|
Ifenprodil (NP-120), a cerebral vasodilator, is a noncompetitive NMDA receptor antagonist. Ifenprodil exerts high affinity at NR1A/NR2B receptors (IC50=0.34 μM) over 400-fold than at NR1A/NR2A receptors (IC50=146 μM) . Ifenprodil is an α1 adrenergic receptor antagonist. Ifenprodil inhibits GIRK (Kir3), reduces inward currents through the basal GIRK activity. Ifenprodil has reliable inhibitory effects against A/H1N1 strains (EC50 of 6.6 µM). Ifenprodil has neuroprotective, anticonvulsant and antinociceptive effects. Ifenprodil can be used for the study of cerebrovascular diseases and peripheral arterial obliterative disease .
|
-
-
- HY-108506
-
|
BIA 2-005; GP 47779
|
Sodium Channel
|
Neurological Disease
|
|
Licarbazepine (BIA 2-005; GP 47779) is a voltage-gated sodium channel blocker with anticonvulsant and mood-stabilizing effects .
|
-
-
- HY-108707
-
|
|
iGluR
|
Neurological Disease
|
|
LY3130481 is an orally available AMPA receptor antagonist, selectively inhibiting the IC50 value of AMPA/TARP γ-8 at 65 nM. LY3130481 has anticonvulsant, antiepileptic, and pain-relieving effects .
|
-
-
- HY-136591
-
|
|
Drug Metabolite
|
Neurological Disease
Cancer
|
|
Demoxepam is a major metabolite of Chlordiazepoxide. Demoxepam exhibits cytotoxicity activity against cancer cell lines. Demoxepam has anticonvulsant and anxiolytic effects. Demoxepam has an inhibitory effect on in vitro [ 3H]tryptophan binding to rat hepatic nuclei .
|
-
-
- HY-N8303
-
|
|
ERK
PAK
|
Neurological Disease
Inflammation/Immunology
|
|
Gardenin A is an orally active and synthetic PMF analogue with the neurotrophic effect for neurite outgrowth and neuronal differentiation. Gardenin A promotes neuritogenesis via activating MAPK/ERK, PKC, and PKA, but not TrkA, CREB signaling pathways. Gardenin A also has sedative, anxiolytic, antidepressant, and anticonvulsant effects .
|
-
-
- HY-P1334A
-
-
-
- HY-152358
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
N3-Methyl-2’-O-methyluridine is a uridine analogue. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
-
- HY-107515A
-
|
|
mGluR
|
Neurological Disease
|
|
LY367385 hydrochloride is a highly selective and potent mGluR1a antagonist. LY367385 hydrochloride has an IC50 of 8.8 μM for inhibiting of quisqualate-induced phosphoinositide (PI) hydrolysis, compared with >100 μM for mGlu5a. LY367385 hydrochloride has neuroprotective, anticonvulsant and antiepileptic effects .
|
-
-
- HY-W012481
-
|
Ethylphenylhydantoin; Phenylethyihydantoin; Desmethylmephenytoin
|
Drug Metabolite
|
Neurological Disease
|
|
Nirvanol (Ethylphenylhydantoin) is a metabolite of Mephenytoin (HY-B1184) that exerts anticonvulsant effects in the maximal electroshock (M.E.S.) seizure model in mice. Nirvanol shows potential for research in epilepsy-related neurological disorders .
|
-
-
- HY-141795
-
|
Co 134444
|
Drug Derivative
|
Neurological Disease
|
|
Posovolone (Co 134444) is an orally active, neuroactive steroid. Posovolone has anticonvulsant and anxiolytic-like activity as well as ataxic effects .
|
-
-
- HY-101387
-
|
|
mGluR
|
Neurological Disease
|
|
rel-ACPT-I is an agonist of group III mGluRs with diverse biological activities including neuroprotective, anticonvulsant, and anxiolytic-like effects .
|
-
-
- HY-W436270
-
|
|
Dopamine Receptor
|
Neurological Disease
Inflammation/Immunology
|
|
Bulbocapnine hydrochloride, an aporphine alkaloid, is a dopamine receptor inhibitor. Bulbocapnine hydrochloride inhibits dopamine synthesis. Bulbocapnine hydrochloride also has neuroleptic-like, anticonvulsant and antinociceptive effects .
|
-
-
- HY-14836
-
|
JZP 4
|
Calcium Channel
Sodium Channel
|
Neurological Disease
|
|
Elpetrigine (JZP 4) is a potent calcium and sodium channel blocker. Elpetrigine has anticonvulsant, antidepressant, antimania and anxiolytic effects. Elpetrigine can be used in the research of epilepsy and bipolar disorder .
|
-
-
- HY-107515
-
|
|
mGluR
|
Neurological Disease
|
|
LY367385 is a highly selective and potent mGluR1a antagonist. LY367385 has an IC50 of 8.8 μM for inhibiting of quisqualate-induced phosphoinositide (PI) hydrolysis, compared with >100 μM for mGlu5a. LY367385 has neuroprotective, anticonvulsant and antiepileptic effects .
|
-
-
- HY-134337
-
|
|
Nucleoside Antimetabolite/Analog
Phosphoramidites
|
Cancer
|
|
5'-O-DMTr-3'-O-methyl uridine-3'-CED-phosphoramidite is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
-
- HY-B1283
-
|
|
iGluR
|
Neurological Disease
|
|
Mephenesin is an NMDA receptor antagonist. Mephenesin is also a central muscle relaxant with antianxiety, muscle-paralyzing and anticonvulsant effects. Mephenesin acts directly on the skeletal muscle fibres to produce skeletal muscle relaxation. Mephenesin is promising for research of spasticity or painful muscle spasm .
|
-
-
- HY-152732
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
6-Methyluridine is a uridine analogue. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
-
- HY-108506R
-
|
BIA 2-005 (Standard); GP 47779 (Standard)
|
Reference Standards
Sodium Channel
|
Neurological Disease
|
|
Licarbazepine (Standard) is the analytical standard of Licarbazepine. This product is intended for research and analytical applications. Licarbazepine (BIA 2-005; GP 47779) is a voltage-gated sodium channel blocker with anticonvulsant and mood-stabilizing effects .
|
-
-
- HY-103536
-
|
|
Neuropeptide Y Receptor
|
Neurological Disease
|
|
Galnon is a selective and non-peptide agonist of galanin GAL1 and GAL2 receptor, with Kis of 11.7 and 34.1 μM respectively. Galnon exhibits anticonvulsant and anxiolytic effects .
|
-
-
- HY-154285
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-O-(2-Methoxyethyl) uridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
-
- HY-154466
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5’-O-(4,4’-Dimethoxytrityl)-3’-O-methyluridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
-
- HY-48973
-
|
|
Nucleoside Antimetabolite/Analog
Phosphoramidites
|
Others
|
|
2'-Fluoro-2'-deoxy-ara-U-3'-phosphoramidite is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
-
- HY-154358
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
4’-alpha-C-Allyl-2’,3’-bis(O-t-butyldimethylsilyl) uridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
-
- HY-154492
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’,3’-Bis(O-t-butyldimethylsilyl)-4’,5’-didehydro-5’-deoxyuridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
-
- HY-W749797
-
|
|
GABA Receptor
|
Neurological Disease
|
|
Nitrazolam is a benzodiazepine compound, that may exhibit CNS depressant properties as traditional benzodiazepines, including sedation, hypnosis, anxiolysis, and anticonvulsant effects, by acting on GABA receptors .
|
-
-
- HY-107702
-
|
|
iGluR
|
Neurological Disease
|
|
CGP 37849 is a potent, competitive and orally active N-methyl-D-aspartate (NMDA) receptor antagonist. CGP 37849 is an anticonvulsant in rodents and has antidepressant and anxiolytic-like effects .
|
-
-
- HY-W020098
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2'-C-methyluridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
-
- HY-108506S2
-
-
-
- HY-103536A
-
|
|
Neuropeptide Y Receptor
|
Neurological Disease
|
|
Galnon TFA is a selective and non-peptide agonist of galanin GAL1 and GAL2 receptor, with Kis of 11.7 and 34.1 μM respectively. Galnon TFA exhibits anticonvulsant and anxiolytic effects .
|
-
-
- HY-154488
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3′-O-[(1,1-Dimethylethyl)dimethylsilyl]-2′-O-methyluridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
-
- HY-136471
-
-
-
- HY-W012481R
-
|
Ethylphenylhydantoin (Standard); Phenylethyihydantoin (Standard); Desmethylmephenytoin (Standard)
|
Drug Metabolite
Reference Standards
|
Neurological Disease
|
|
Nirvanol (Ethylphenylhydantoin) is a metabolite of Mephenytoin (HY-B1184) that exerts anticonvulsant effects in the maximal electroshock (M.E.S.) seizure model in mice. Nirvanol shows potential for research in epilepsy-related neurological disorders .
|
-
-
- HY-171253
-
-
-
- HY-N9502R
-
|
|
Reference Standards
Endogenous Metabolite
|
Neurological Disease
|
|
Linalool oxide (Standard) is the analytical standard of Linalool oxide (HY-N9502). This product is intended for research and analytical applications. Linalool oxide is a monoterpene and found in aromatic plant essential oils and is a secondary metabolite in elongating wheat plants. Linalool oxide has antinociceptive, anticonvulsant, and anxiolytic activity. Linalool oxide can be used for the research of pain, epilepsy, anxiety disorders .
|
-
-
- HY-N0491
-
|
(-)-Lupinidine sulfate
|
nAChR
|
Neurological Disease
|
|
(-)-Sparteine (sulfate) is a quinolizidine alkaloid that can be extracted from Lupinus. (-)-Sparteine (sulfate) inhibits the release of acetylcholine and has anticonvulsant effects .
|
-
-
- HY-133160
-
|
VPA-HA
|
Drug Derivative
|
Neurological Disease
|
|
Valproic acid hydroxamate (VPA-HA) has shown anticonvulsant activity in a mouse neural tube defect model, without any teratogenic effects .
|
-
-
- HY-173181
-
|
|
Keap1-Nrf2
|
Neurological Disease
|
|
Anticonvulsant agent 10 (Compound 6d) is an inhibitor targeting the Keap1-Nrf2 interaction, with a potent ED50 of 0.04 mmol/kg. By inhibiting Keap1-Nrf2 binding and activating the Nrf2/ARE pathway, Anticonvulsant agent 10 exerts anticonvulsant and neuroprotective effects, making it suitable for research in antiepileptic and neuroprotective studies .
|
-
-
- HY-120306
-
|
|
AP-1
|
Neurological Disease
|
|
HHL-6 can regulate the overexpression of c-Fos and BDNF proteins. HHL-6 has potent anticonvulsant and antiepileptogenic effects .
|
-
-
- HY-101387A
-
|
|
mGluR
|
Neurological Disease
|
|
ACPT-II is an antagonist of group III mGluRs with diverse biological activities including neuroprotective, anticonvulsant, and anxiolytic-like effects .
|
-
- HY-108506S1
-
-
- HY-108506S
-
|
BIA 2-005-d3; GP 47779-d3
|
Sodium Channel
|
Neurological Disease
|
|
Licarbazepine-d3 is the deuterium labeled Licarbazepine (HY-108506). Licarbazepine is a voltage-gated sodium channel blocker with anticonvulsant and mood-stabilizing effects .
|
-
- HY-165514
-
|
|
Sodium Channel
|
Neurological Disease
|
|
Nafimidone is a stable and brain-penetrant antiepileptic compound Nafimidone shows effective anticonvulsant effects in kindled amygdaloid seizure model. However, The effective window of Nafimidone is narrow, and has obvious epileptogenic effects at high doses. Nafimidone can be used for the study of epilepsy .
|
-
- HY-152755
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
4’-Cyanouridine is a uridine analogue. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-152764
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
4’-α-C-Methyluridine is a uridine analogue. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-152777
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
5’(R)-C-Methyluridine is a uridine analogue. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-152299
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
5-(t-Butyloxycarbonylmethoxy)uridine is a uridine analogue. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-119105
-
|
|
GABA Receptor
|
Neurological Disease
|
|
LY81067, a diaryltriazine, effectively protects against Pentylenetetrazole- and Picrotoxin-induced convulsions in mice. LY81067 exerts its anticonvulsant effects by binding to or near Picrotoxin (HY-101391) binding sites .
|
-
- HY-154735
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N3-Allyluridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-152388
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3’-beta-C-Methyluridine is a uridine analogue. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-152665
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
1-(β-D-Xylofuranosyl)uracil is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-152970
-
|
|
Nucleoside Antimetabolite/Analog
Phosphoramidites
|
Others
|
|
7'-O-DMT-morpholino uracil is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-149077
-
|
|
Others
|
Others
|
|
2′-Deoxy-5-methoxyuridine is a uridine analogue. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-154734
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N3-(4-Nitrobenzyl)uridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-W557556
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2',5'-Bis-O-(triphenylMethyl)uridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-152677
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
N3-(2-Methoxy)ethyluridine is a uridine analogue. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-154217
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3′,5′-Bis-O-(triphenylmethyl)uridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-152529
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
4’-C-Methyl-5-methoxyuridine is a uridine analogue. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-152522
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
5-Fluoro-4’-C-methyluridine is a uridine analogue. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-117162
-
|
|
Cholinesterase (ChE)
|
Neurological Disease
|
|
S 1432 is a central nervous system depressant with anticonvulsant and muscle relaxant effects. S 1432 significantly reduces acetylcholine levels in the striatum inhibits convulsions induced by pentylenetetrazol. S 1432 can be used in the development of psychotropic drugs .
|
-
- HY-154738
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N3-[3-(tert-Butoxycarbonyl)amino]propyluridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-152783
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
5’(R)-C-Methyl-5-fluorouridine is a uridine analogue. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-152969
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
6-Chloro-N1-(trimethylsilylethoxymethyl)pseudouridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-152779
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
5-Methoxy-5’(R)-C-methyluridine is a uridine analogue. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-108506S4
-
-
- HY-152798
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
5-Iodo-2’-β-C-methyl uridine is a uridine analogue. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-154737
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N3-[(Pyrid-4-yl)methyl]uridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-152681
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
N3-[(Tetrahydro-2-furanyl)methyl]uridine is a uridine analogue. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-152463
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
4′-C-2-Propen-1-yluridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-106885
-
|
|
Drug Derivative
|
Neurological Disease
|
|
F 2692 is an orally effective derivative of pyridazine. F 2692 has significant anti anxiety effects. F 2692 also has activities such as anticonvulsant, sedative, and muscle relaxant. F 2692 can be used for research on neurological disorders such as anxiety disorders .
|
-
- HY-152683
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
N3-[(Pyrid-2-yl)methyl]uridine is a uridine analogue. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-152574
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
5-Amino-2’-deoxy-2’-O-methyluridine hydrochloride is a uridine analogue. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-152674
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2′-Deoxy-2′-fluoro-5-methoxy-arabinouridine is a uridine analogue. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-154560
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’,3’,5’-Tri-O-acetyl-N3-methyluridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-161896
-
|
|
GABA Receptor
|
Neurological Disease
|
|
Transcription factor-IN-1 (Compound 4e) is an inhibitor for transcription factor. Transcription factor-IN-1 exhibits anticonvulsant activity by antagonism with pentylenetetrazole (PTZ) (ED50 =34.5 mg/kg). Transcription factor-IN-1 exhibits antidepressant effects in rat models .
|
-
- HY-152363
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
N3-Methyl-2’-O-(2-methoxyethyl)uridine is a uridine analogue. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-154173
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-O-(t-Butyldimethylsilyl)-2’-O-(2-methoxyethyl) uridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-118974
-
|
|
Calcium Channel
|
Neurological Disease
Cancer
|
|
PD-151307 is an N-type calcium channel antagonist with significant inhibitory effects in IMR-32 human neuroblastoma cells, exhibiting an IC50 of 0.32 µM. PD-151307 can be used in research related to cancer therapy, anticonvulsants, and neuropathic pain .
|
-
- HY-154813
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3′,5′-Di-O-acetyl-2′-deoxy-2′-fluorouridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-49199
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2',3',5'-Tri-O-(t-butyldimethylsilyl)-4'-C-hydroxymethyl uridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-U00199A
-
|
(S)-N-Desmethyl zopiclone; SEP-174559
|
GABA Receptor
nAChR
iGluR
|
Neurological Disease
|
|
(S)-Norzopiclone ((S)-N-Desmethyl zopiclone; SEP-174559) is a metabolite of Zopiclone with anxiolytic and anticonvulsant effects. (S)-Norzopiclone has benzodiazepine-like actions at γ2-bearing subtypes of the GABAA receptor and inhibits nACh and NMDA receptors .
|
-
- HY-B0114S1
-
-
- HY-154410
-
|
|
Nucleoside Antimetabolite/Analog
Phosphoramidites
|
Cancer
|
|
5’-O-DMT-2’-deoxy-2’-fluoro-β-D-arabinouridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-152691
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2’-Deoxy-2’-fluoro-N3-(n-dodecyl)-beta-D-arabinouridine is a uridine analogue. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-182023
-
|
|
Reactive Oxygen Species (ROS)
GABA Receptor
|
Neurological Disease
|
|
Anticonvulsant agent 11 (Compound 8b) is an anticonvulsant agent. Anticonvulsant agent 11 exerts neuroprotective effects by enhancing cell viability and reducing ROS levels. Anticonvulsant agent 11 induces the expression of GABAA α1, resulting in neuronal hyperpolarization. Anticonvulsant agent 11 increases the number of neurite-bearing cells and the length of neurites. Anticonvulsant agent 11 exhibits dose-dependent anticonvulsant effects in mice. Anticonvulsant agent 11 can be used for the research of epilepsy .
|
-
- HY-165514A
-
|
|
Cholinesterase (ChE)
|
Neurological Disease
|
|
Nafimidone is a stable and brain-penetrant antiepileptic compound. Nafimidone shows effective anticonvulsant effects in kindled amygdaloid seizure model. Nafimidone exhibits the narrow effective window, and has obvious epileptogenic effects at high doses. Nafimidone can be used for the study of epilepsy .
|
-
- HY-181828
-
|
|
iGluR
Dopamine Receptor
|
Neurological Disease
|
|
SePP is a blood-brain barrier-permeable NMDAR antagonist and dopamine/norepinephrine reuptake inhibitor, with a Ki of 28.7 nM for rat NMDAR. SePP exerts anticonvulsant effects. SePP can be used in research related to fragile X syndrome .
|
-
- HY-105693
-
|
|
iGluR
|
Neurological Disease
|
|
Fluorofelbamate, a Felbamate (HY-B0184) analog, is a potent NMDA receptor antagonist. Fluorofelbamate exhibits anticonvulsant and antiepileptogenic effects in an experimental rat model of self-sustaining status epilepticus (SSSE). Fluorofelbamate can be used for epilepsy research .
|
-
- HY-114542
-
|
|
Drug Derivative
|
Others
|
|
LY 201409 is an anticonvulsant compound that is an analog of LY-201116 (HY-114705) with improved metabolic activity. LY 201409 antagonizes maximal electroconvulsive-induced seizures, has mixed effects on seizures induced by multiple chemoconvulsants, and affects behavior and sleep in mice .
|
-
- HY-171182
-
|
|
Endogenous Metabolite
|
Neurological Disease
|
|
D3017 is the main metabolite of D2624, which has oral bioactivity and anti-convulsant effects. D3017 ED50 value is 1.5 mg/kg in mice, and it can be used for research on severe generalized tonic-clonic seizures (grand mal) and complex partial epilepsy .
|
-
- HY-114883
-
|
L-Homocarnosine
|
GABA Receptor
Endogenous Metabolite
|
Neurological Disease
Inflammation/Immunology
|
|
Homocarnosine is a dipeptide of γ-aminobutyric acid (GABA) and histidine unique to brain. Homocarnosine is an inhibitory neuromodulator synthesized in the neuron from GABA and exhibiting anticonvulsant effects .Homocarnosine has antioxidant and anti-inflammatory actions, prevention of DNA damage, and inhibition of advanced glycation end-product formation .
|
-
- HY-B0114R
-
|
GP 47680 (Standard)
|
Reference Standards
Sodium Channel
Apoptosis
|
Neurological Disease
Cancer
|
|
Oxcarbazepine (Standard) is the analytical standard of Oxcarbazepine. This product is intended for research and analytical applications. Oxcarbazepine is a sodium channel blocker . Oxcarbazepine significantly inhibits glioblastoma cell growth and induces apoptosis or G2/M arrest in glioblastoma cell lines . Anti-cancer and anticonvulsant effects .
|
-
- HY-B2117
-
|
|
Epoxide Hydrolase
EBV
|
Infection
Neurological Disease
|
|
Valpromide is an amide derivative of Valproic acid (HY-10585) and an orally active epoxide hydrolase inhibitor that can cross the blood-brain barrier. Valpromide has antiepileptic, anticonvulsant, and antipsychotic effects. Valpromide also exhibits antiviral activity and can inhibit the reactivation of the EBV lytic cycle .
|
-
- HY-154175
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
1-[6-(Diethoxyphosphinyl)-2-O-(2-methoxyethyl)-β-D-ribo-hexofuranosyl]uracil is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-114883A
-
|
L-Homocarnosine TFA
|
GABA Receptor
Endogenous Metabolite
|
Neurological Disease
|
|
Homocarnosine TFA is a dipeptide of γ-aminobutyric acid (GABA) and histidine unique to brain. Homocarnosine TFA is an inhibitory neuromodulator synthesized in the neuron from GABA and exhibiting anticonvulsant effects . Homocarnosine TFA has antioxidant and anti-inflammatory actions, prevention of DNA damage, and inhibition of advanced glycation end-product formation .
|
-
- HY-152792
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2’-Deoxy-2’-fluoro-N3-[(pyrid-2-yl)methyl]uridine is a uridine analogue. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-154552
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-O-Acetyl-5’-O-benzoyl-3’-O-(2-methoxyethyl) uridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-108964R
-
|
|
Reference Standards
Bacterial
|
Infection
Neurological Disease
Inflammation/Immunology
|
|
Carvone (Standard) is the analytical standard of Carvone. This product is intended for research and analytical applications. Carvone is a ketone monoterpene found mostly in the essential oils from plants of the genus Mentha. Carvone is widely used in the pharmaceutical industry, cosmetics and agriculture. Carvone has such effects as antimicrobial, antioxidant, anti-inflammatory, antispasmodic, antinociceptive, anticonvulsant .
|
-
- HY-B0114S3
-
|
GP 47680-d10
|
Isotope-Labeled Compounds
Apoptosis
Sodium Channel
|
Neurological Disease
Cancer
|
|
Oxcarbazepine-d10 (GP 47680-d10) is deuterium labeled Oxcarbazepine. Oxcarbazepine is a sodium channel blocker . Oxcarbazepine significantly inhibits glioblastoma cell growth and induces apoptosis or G2/M arrest in glioblastoma cell lines . Anti-cancer and anticonvulsant effects .
|
-
- HY-B0114S
-
|
GP 47680-d4
|
Isotope-Labeled Compounds
Sodium Channel
Apoptosis
|
Neurological Disease
Cancer
|
|
Oxcarbazepine-d4 (GP 47680-D4) is the deuterium labeled Oxcarbazepine. Oxcarbazepine is a sodium channel blocker . Oxcarbazepine significantly inhibits glioblastoma cell growth and induces apoptosis or G2/M arrest in glioblastoma cell lines . Anti-cancer and anticonvulsant effects .
|
-
- HY-Y1267D
-
-
- HY-B0114S2
-
|
GP 47680-d8
|
Sodium Channel
Apoptosis
|
Neurological Disease
Cancer
|
|
Oxcarbazepine-d8-1 is a deuterium of Oxcarbazepine. Oxcarbazepine is a sodium channel blocker . Oxcarbazepine significantly inhibits glioblastoma cell growth and induces apoptosis or G2/M arrest in glioblastoma cell lines . Oxcarbazepine-d8-1 has anti-cancer and anticonvulsant effects .
|
-
- HY-154517
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N3-Cyanoethyl-5’-O-(4,4’-dimethoxytrityl)-2’-O-methyluridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-A0042R
-
|
CGP 33101 (Standard); E 2080 (Standard); RUF 331 (Standard)
|
Sodium Channel
Reference Standards
|
Neurological Disease
|
|
Rufinamide (Standard) is the analytical standard of Rufinamide (HY-A0042). This product is intended for research and analytical applications. Rufinamide (CGP 33101) is an orally active antiepileptic compound that inhibits Na + current activation, inhibits neuronal hyperexcitability, and has anticonvulsant effects. Rufinamide is used in the study of Lennox-Gastaut syndrome .
|
-
- HY-154647
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N3-(2S)-[2-(tert-Butoxycarbonyl)amino-3-(tert-butoxy carbonyl)]propyluridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-182548
-
|
|
GABA Receptor
Sodium Channel
iGluR
|
Cardiovascular Disease
Neurological Disease
|
|
BTS 72664 is a broad-spectrum, non-sedating, orally effective anticonvulsant. Its anticonvulsant effect mainly arises from enhancing GABAA receptor (GABAA receptor)-mediated chloride channel currents, while it exerts weak blocking effects on Na + channels (Ki = 350 μM) and NMDA receptors (NMDA receptor) (IC50 = 43 μM). BTS 72664 prevents the elevation of extracellular glutamate, glycine and serine concentrations in neurons, reduces cerebral infarct size, promotes functional recovery, prevents multiple types of epileptic seizures, and has low sedative potential. BTS 72664 can be used for the research of epilepsy, stroke and migraine .
|
-
- HY-154582
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
5-Naphthyl-beta-methylaminocarbony-3’-O-acetyl-2’-O-methyl-5’-O-DMTr-uridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-A0092R
-
|
3,5,5,-Trimethyloxazolidine-2,4-dione (Standard)
|
Reference Standards
Calcium Channel
|
Neurological Disease
|
|
Trimethadione (Standard) is the analytical standard of Trimethadione. This product is intended for research and analytical applications. Trimethadione (3,5,5,-Trimethyloxazolidine-2,4-dione) is an oxazolidinedione anticonvulsant agent widely used against absences seizures. Trimethadione also is a T-type calcium channel blocker which has antihyperalgesic effects .
|
-
- HY-136591R
-
|
|
Drug Metabolite
Reference Standards
|
Neurological Disease
Cancer
|
|
Demoxepam (Standard) is the analytical standard of Demoxepam. This product is intended for research and analytical applications. Demoxepam is a major metabolite of Chlordiazepoxide. Demoxepam exhibits cytotoxicity activity against cancer cell lines. Demoxepam has anticonvulsant and anxiolytic effects. Demoxepam has an inhibitory effect on in vitro [ 3H]tryptophan binding to rat hepatic nuclei .
|
-
- HY-103536AR
-
|
|
Reference Standards
Neuropeptide Y Receptor
|
Neurological Disease
|
|
Galnon TFA (Standard) is the analytical standard of Galnon TFA (HY-103536A). This product is intended for research and analytical applications. Galnon TFA is a selective and non-peptide agonist of galanin GAL1 and GAL2 receptor, with Kis of 11.7 and 34.1 μM respectively. Galnon TFA exhibits anticonvulsant and anxiolytic effects .
|
-
- HY-N16538
-
|
|
Drug Derivative
|
Cardiovascular Disease
Neurological Disease
|
|
4-(Acetoxymethyl)phenyl glucoside is a type of gastrodin derivative that can cross the blood-brain barrier. 4-(Acetoxymethyl)phenyl glucoside exhibits sedative, anticonvulsant and analgesic effects in mouse models. 4-(Acetoxymethyl)phenyl glucoside can be used for research on senile cardiovascular and cerebrovascular diseases as well as brain nerve disorders .
|
-
- HY-A0042S
-
|
CGP 33101-d2; E 2080-d2; RUF 331-d2
|
Isotope-Labeled Compounds
Sodium Channel
|
Neurological Disease
|
|
Rufinamide-d2 (CGP 33101-d2) is the deuterium labeled Rufinamide (HY-A0042). Rufinamide (CGP 33101) is an orally active antiepileptic compound that inhibits Na + current activation, inhibits neuronal hyperexcitability, and has anticonvulsant effects. Rufinamide is used in the study of Lennox-Gastaut syndrome .
|
-
- HY-A0177
-
|
|
GABA Receptor
|
Inflammation/Immunology
|
|
Fominoben is a type of benzamide-based antitussive agent. Fominoben works by acting on the central nervous system to increase alveolar ventilation, thereby improving the blood oxygen levels in patients with pulmonary diseases (COLD). Fominoben can bind to the benzodiazepine receptor binding sites in the brain and also has anti-anxiety and anti-convulsant effects. Fominoben can be used in research on hypoxemia.
|
-
- HY-108707R
-
|
|
Reference Standards
iGluR
|
Neurological Disease
|
|
LY3130481 (Standard) is the analytical standard of LY3130481 (HY-108707). This product is intended for research and analytical applications. LY3130481 is an orally available AMPA receptor antagonist, selectively inhibiting the IC50 value of AMPA/TARP γ-8 at 65 nM. LY3130481 has anticonvulsant, antiepileptic, and pain-relieving effects .
|
-
- HY-W012481S
-
|
Ethylphenylhydantoin-d5; Phenylethyihydantoin-d5; Desmethylmephenytoin-d5
|
Isotope-Labeled Compounds
Drug Metabolite
|
Neurological Disease
|
|
Nirvanol-d5 (Ethylphenylhydantoin-d5) is deuterium labeled Nirvanol (HY-W012481) . Nirvanol (Ethylphenylhydantoin) is a metabolite of Mephenytoin (HY-B1184) that exerts anticonvulsant effects in the maximal electroshock (M.E.S.) seizure model in mice. Nirvanol shows potential for research in epilepsy-related neurological disorders .
|
-
- HY-B1283S
-
|
|
Isotope-Labeled Compounds
iGluR
|
Neurological Disease
|
|
Mephenesin-d3 is deuterium labeled Mephenesin. Mephenesin is an NMDA receptor antagonist. Mephenesin is also a central muscle relaxant with antianxiety, muscle-paralyzing and anticonvulsant effects. Mephenesin acts directly on the skeletal muscle fibres to produce skeletal muscle relaxation. Mephenesin is promising for research of spasticity or painful muscle spasm .
|
-
- HY-122114
-
|
|
Potassium Channel
|
Neurological Disease
|
|
ICA-27243 is a selective, potent and orally active KCNQ2/Q3 potassium channel opener with an EC50 of 0.38 μM. ICA-27243 is less effective at activating KCNQ4 and KCNQ3/Q5. ICA-27243 has antiepileptic and anticonvulsant effects .
|
-
- HY-121141
-
|
|
nAChR
|
Neurological Disease
|
|
Adiphenine is a non-competitive inhibitor of nicotinic acetylcholine receptor (nAChR), with an IC50s of 1.9, 1.8, 3.7, and 6.3 μM for α1, α3β4, α4β2, and α4β4, respectively. Adiphenine has anticonvulsant effects .
|
-
- HY-160978
-
|
KC-7507 free base
|
GABA Receptor
|
Neurological Disease
|
|
Timelotem (KC-7507 free base) is a representative of a class of 1, 2-cyclo1, 4-benzodiazepines. Timelotem shows significant antipsychotic properties. Timelotem produces sedative, anti-anxiety and anti-convulsant effects by enhancing the action of the neurotransmitter gamma-aminobutyric acid (GABA). Timelotem can be used in studies of schizophrenia and other mental disorders .
|
-
- HY-B0379A
-
|
|
nAChR
|
Neurological Disease
|
|
Adiphenine hydrochloride is a non-competitive inhibitor of nicotinic acetylcholine receptor (nAChR), with an IC50s of 1.9, 1.8, 3.7, and 6.3 μM for α1, α3β4, α4β2, and α4β4, respectively. Adiphenine hydrochloride has anticonvulsant effects .
|
-
- HY-114975
-
|
|
iGluR
|
Neurological Disease
|
|
EGIS-8332 is a non-competitive AMPA receptor antagonist. EGIS-8332 inhibits AMPA currents in rat cerebellar Purkinje cells and inhibited the AMPA- and Quisqualate-induced excitotoxicity in primary cultures of telencephalon neurons (IC50 = 5.1-9.0 μM). EGIS-8332 exhibits anticonvulsant and neuroprotective effects. EGIS-8332 can be used for the research of neurological disease .
|
-
- HY-154652
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
1-(2,3,5-Tri-O-benzoyl-2-C-methyl-β-D-ribofuranosyl)-2,4(1H,3H)-pyrimidinedione is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-P10698
-
|
|
Peptide-Drug Conjugates (PDCs)
LDLR
|
Neurological Disease
|
|
VH-N412 is a vectorized neuropeptide (NT) with good blood-brain barrier permeability. VH-N412 binds to the low-density lipoprotein receptor (LDLR) and neuropeptide receptor 1 (NTSR-1), and acts as a pharmacological-induced hypothermia (PIH) inducer. VH-N412 exhibits anticonvulsant and neuroprotective effects, and can be used in the study of neurological diseases such as epilepsy.
|
-
- HY-152476
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-β-C-Ethynyluridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents . 3’-β-C-Ethynyluridine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-B0696A
-
|
NO050328 hydrochloride; NO328 hydrochloride; TGB hydrochloride
|
GABA Receptor
|
Neurological Disease
|
|
Tiagabine hydrochloride (NO050328; NO328; TGB) is an orally active, highly selective, and reversible GAT-1 inhibitor and anticonvulsant that crosses the blood-brain barrier. By blocking the reuptake of GABA in neurons and glial cells, tiagabine increases extracellular GABA levels to enhance inhibitory signal transduction, thereby exerting multiple activities such as anticonvulsant, neuroprotective, and antioxidant effects. Tiagabine hydrochloride exhibits linear pharmacokinetic properties. Although it is metabolized by CYP3A and has a high protein binding rate, it carries a low risk of cognitive impairment. Tiagabine hydrochloride is widely used in research on related diseases including epilepsy (including refractory partial seizures), alcohol withdrawal symptoms, and Huntington's disease .
|
-
- HY-B0696B
-
|
NO050328 hydrochloride hydrate; NO328 hydrochloride hydrate; TGB hydrochloride hydrate
|
GABA Receptor
|
Neurological Disease
|
|
Tiagabine (NO050328; NO328; TGB) hydrochloride hydrate is an orally active, highly selective, and reversible GAT-1 inhibitor and anticonvulsant that crosses the blood-brain barrier. By blocking the reuptake of GABA in neurons and glial cells, tiagabine increases extracellular GABA levels to enhance inhibitory signal transduction, thereby exerting multiple activities such as anticonvulsant, neuroprotective, and antioxidant effects. Tiagabine hydrochloride hydrate exhibits linear pharmacokinetic properties. Although it is metabolized by CYP3A and has a high protein binding rate, it carries a low risk of cognitive impairment. Tiagabine hydrochloride hydrate is widely used in research on related diseases including epilepsy (including refractory partial seizures), alcohol withdrawal symptoms, and Huntington's disease .
|
-
- HY-B0696
-
|
NO050328; NO328; TGB
|
GABA Receptor
|
Neurological Disease
|
|
Tiagabine (NO050328; NO328; TGB) is an orally active, highly selective, and reversible GAT-1 inhibitor and anticonvulsant that crosses the blood-brain barrier. By blocking the reuptake of GABA in neurons and glial cells, tiagabine increases extracellular GABA levels to enhance inhibitory signal transduction, thereby exerting multiple activities such as anticonvulsant, neuroprotective, and antioxidant effects. Tiagabine exhibits linear pharmacokinetic properties. Although it is metabolized by CYP3A and has a high protein binding rate, it carries a low risk of cognitive impairment. Tiagabine is widely used in research on related diseases including epilepsy (including refractory partial seizures), alcohol withdrawal symptoms, and Huntington's disease .
|
-
- HY-105056
-
|
Ro 16-6028
|
GABA Receptor
|
Neurological Disease
|
|
Bretazenil (Ro 16-6028) is a partial agonist at the gamma-aminobutyric acid A (GABAA) receptor-linked benzodiazepine site. Bretazenil is potent benzodiazepine examined, exhibiting an IC50 (concentration at which half-maximal inhibition of specific [35S]TBPS binding occurs) of 6.1 nM. Bretazenil shows an EC50 of 10 nM for recombinant α1β1γ2. Anticonvulsant effects .
|
-
- HY-107515AR
-
|
|
Reference Standards
mGluR
|
Neurological Disease
|
|
LY367385 hydrochloride (Standard) is the analytical standard of LY367385 (hydrochloride) (HY-107515A). This product is intended for research and analytical applications. LY367385 hydrochloride is a highly selective and potent mGluR1a antagonist. LY367385 hydrochloride has an IC50 of 8.8 μM for inhibiting of quisqualate-induced phosphoinositide (PI) hydrolysis, compared with >100 μM for mGlu5a. LY367385 hydrochloride has neuroprotective, anticonvulsant and antiepileptic effects .
|
-
- HY-B2117R
-
|
|
Reference Standards
Epoxide Hydrolase
EBV
|
Infection
Neurological Disease
|
|
Valpromide (Standard) is the analytical standard of Valpromide (HY-B2117). This product is intended for research and analytical applications. Valpromide is an amide derivative of Valproic acid (HY-10585) and an orally active epoxide hydrolase inhibitor that can cross the blood-brain barrier. Valpromide has antiepileptic, anticonvulsant, and antipsychotic effects. Valpromide also exhibits antiviral activity and can inhibit the reactivation of the EBV lytic cycle .
|
-
- HY-B1606
-
|
Chlorthymol; 6-Chlorothymol
|
Environmental Pollutants
Bacterial
AP-1
GABA Receptor
|
Infection
Neurological Disease
|
|
Chlothymol is a potent positive modulator of the GABAA receptor subunit LGC-37, anticonvulsant, and antibacterial agent. Chlothymol inhibits Pentylenetetrazol-induced c-fos expression. Chlothymol inhibits the growth of Methicillin (HY-121544)-resistant Staphylococcus aureus (MRSA) strains, including LAC, with an MIC of 32 μg/mL. Chlorothymol has protective effects against epileptic seizures in various mouse models .
|
-
- HY-158252S
-
|
NO050328-d5 hydrochloride; NO328-d5 hydrochloride; TGB-d5 hydrochloride
|
Isotope-Labeled Compounds
GABA Receptor
|
Neurological Disease
|
|
Tiagabine-d5 (hydrochloride) is deuterium labeled Tiagabine (hydrochloride). Tiagabine hydrochloride (NO050328; NO328; TGB) is an orally active, highly selective, and reversible GAT-1 inhibitor and anticonvulsant that crosses the blood-brain barrier. By blocking the reuptake of GABA in neurons and glial cells, tiagabine increases extracellular GABA levels to enhance inhibitory signal transduction, thereby exerting multiple activities such as anticonvulsant, neuroprotective, and antioxidant effects. Tiagabine hydrochloride exhibits linear pharmacokinetic properties. Although it is metabolized by CYP3A and has a high protein binding rate, it carries a low risk of cognitive impairment. Tiagabine hydrochloride is widely used in research on related diseases including epilepsy (including refractory partial seizures), alcohol withdrawal symptoms, and Huntington's disease .
|
-
- HY-A0042S1
-
|
CGP 33101-15N,d2; E 2080-15N,d2; RUF 331-15N,d2
|
Isotope-Labeled Compounds
Sodium Channel
|
Neurological Disease
|
|
Rufinamide- 15N,d2 (CGP 33101- 15N,d2) is the deuterium and 15N labeled Rufinamide (HY-A0042).Rufinamide (CGP 33101) is an orally active antiepileptic compound that inhibits Na + current activation, inhibits neuronal hyperexcitability, and has anticonvulsant effects. Rufinamide is used in the study of Lennox-Gastaut syndrome .
|
-
- HY-105857
-
|
|
GABA Receptor
|
Neurological Disease
|
|
Thiazesim is a benzothiazepine compound with a thiophene structure and acts as a GABAA receptor inhibitor, exerting anticonvulsant and antidepressant effects. Thiazesim exhibits specific pharmacological properties in animal experiments. Thiazesim reduces motor activity in rats and effectively inhibits rat killing responses, with a ratio of 2.1 between the ED50 in rotarod tests and the ED50 for anti-killing behavior. Thiazesim can be widely used in basic and clinical studies related to epilepsy .
|
-
- HY-105857A
-
|
|
GABA Receptor
|
Neurological Disease
|
|
Thiazesim hydrochloride is a benzothiazepine compound with a thiophene structure and acts as a GABAA receptor inhibitor, exerting anticonvulsant and antidepressant effects. Thiazesim hydrochloride exhibits specific pharmacological properties in animal experiments. Thiazesim hydrochloride reduces motor activity in rats and effectively inhibits rat killing responses, with a ratio of 2.1 between the ED50 in rotarod tests and the ED50 for anti-killing behavior. Thiazesim hydrochloride can be widely used in basic and clinical studies related to epilepsy .
|
-
- HY-A0042S2
-
|
CGP 33101-15N,d2-1; E 2080-15N,d2-1; RUF 331-15N,d2-1
|
Isotope-Labeled Compounds
Sodium Channel
|
Neurological Disease
|
|
Rufinamide- 15N,d2-1 (CGP 33101- 15N,d2-1) is 15N- and deuterium-labeled Rufinamide (HY-A0042).Rufinamide (CGP 33101) is an orally active antiepileptic compound that inhibits Na + current activation, inhibits neuronal hyperexcitability, and has anticonvulsant effects. Rufinamide is used in the study of Lennox-Gastaut syndrome .
|
-
- HY-D0803
-
|
|
Apoptosis
VEGFR
PI3K
Akt
|
Infection
Cardiovascular Disease
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Thymoquinone is an orally active natural product isolated from N. sativa Thymoquinone down-regulates the VEGFR2-PI3K-Akt pathway. Thymoquinone has antioxidant, anti-inflammatory, anticancer, antiviral, anticonvulsant, antifungal, antiviral, antiangiogenic activity and hepatoprotective effects. Thymoquinone can be used to study Alzheimer's disease, cancer, cardiovascular disease, infectious disease and inflammation .
|
-
- HY-19259
-
|
|
Adenosine Kinase
|
Neurological Disease
|
|
GP3269 is a selective and orally active human adenosine kinase (AK) inhibitor with an IC50 of 11 nM against human adenosine kinase. GP3269 increases adenosine levels at epileptic foci, activates A1 receptors on excitatory neurons, and exhibits anticonvulsant activity in rats. GP3269 does not induce hemodynamic effects including changes in blood pressure or heart rate in rats. GP3269 can be used for epilepsy-related research .
|
-
- HY-111751
-
|
|
iGluR
|
Neurological Disease
|
|
JNJ-61432059 is a blood-brain barrier-permeable, orally active TARP γ-8-associated AMPAR modulator with anticonvulsant activity. JNJ-61432059 negatively regulates GluA1 and positively modulates GluA2-containing AMPARs. JNJ-61432059 exerts potent protective effects in rodent epilepsy models. JNJ-61432059 is applicable for epilepsy-related research .
|
-
- HY-B0696S1
-
|
NO050328-d4; NO328-d4; TGB-d4
|
Isotope-Labeled Compounds
GABA Receptor
|
Neurological Disease
|
|
Tiagabine-d4 (NO050328-d4) is deuterium labeled Tiagabine. Tiagabine (NO050328; NO328; TGB) is an orally active, highly selective, and reversible GAT-1 inhibitor and anticonvulsant that crosses the blood-brain barrier. By blocking the reuptake of GABA in neurons and glial cells, tiagabine increases extracellular GABA levels to enhance inhibitory signal transduction, thereby exerting multiple activities such as anticonvulsant, neuroprotective, and antioxidant effects. Tiagabine exhibits linear pharmacokinetic properties. Although it is metabolized by CYP3A and has a high protein binding rate, it carries a low risk of cognitive impairment. Tiagabine is widely used in research on related diseases including epilepsy (including refractory partial seizures), alcohol withdrawal symptoms, and Huntington's disease .
|
-
- HY-B0696S
-
|
NO050328-d6; NO328-d6; TGB-d6
|
Isotope-Labeled Compounds
GABA Receptor
|
Neurological Disease
|
|
Tiagabine-d6 (NO050328-d6) is deuterium labeled Tiagabine. Tiagabine (NO050328; NO328; TGB) is an orally active, highly selective, and reversible GAT-1 inhibitor and anticonvulsant that crosses the blood-brain barrier. By blocking the reuptake of GABA in neurons and glial cells, tiagabine increases extracellular GABA levels to enhance inhibitory signal transduction, thereby exerting multiple activities such as anticonvulsant, neuroprotective, and antioxidant effects. Tiagabine exhibits linear pharmacokinetic properties. Although it is metabolized by CYP3A and has a high protein binding rate, it carries a low risk of cognitive impairment. Tiagabine is widely used in research on related diseases including epilepsy (including refractory partial seizures), alcohol withdrawal symptoms, and Huntington's disease .
|
-
- HY-B0696AS
-
|
NO050328-d4 hydrochloride; NO328-d4 hydrochloride; TGB-d4 hydrochloride
|
Isotope-Labeled Compounds
GABA Receptor
|
Neurological Disease
|
|
Tiagabine-d4 hydrochloride is deuterated labeled Tiagabine hydrochloride (HY-B0696A). Tiagabine hydrochloride (NO050328; NO328; TGB) is an orally active, highly selective, and reversible GAT-1 inhibitor and anticonvulsant that crosses the blood-brain barrier. By blocking the reuptake of GABA in neurons and glial cells, tiagabine increases extracellular GABA levels to enhance inhibitory signal transduction, thereby exerting multiple activities such as anticonvulsant, neuroprotective, and antioxidant effects. Tiagabine hydrochloride exhibits linear pharmacokinetic properties. Although it is metabolized by CYP3A and has a high protein binding rate, it carries a low risk of cognitive impairment. Tiagabine hydrochloride is widely used in research on related diseases including epilepsy (including refractory partial seizures), alcohol withdrawal symptoms, and Huntington's disease .
|
-
- HY-B0696AR
-
|
NO050328 hydrochloride (Standard); NO328 hydrochloride (Standard); TGB hydrochloride (Standard)
|
Reference Standards
GABA Receptor
|
Neurological Disease
|
|
Tiagabine (hydrochloride) (Standard) is the analytical standard of Tiagabine (hydrochloride). This product is intended for research and analytical applications. Tiagabine hydrochloride (NO050328; NO328; TGB) is an orally active, highly selective, and reversible GAT-1 inhibitor and anticonvulsant that crosses the blood-brain barrier. By blocking the reuptake of GABA in neurons and glial cells, tiagabine increases extracellular GABA levels to enhance inhibitory signal transduction, thereby exerting multiple activities such as anticonvulsant, neuroprotective, and antioxidant effects. Tiagabine hydrochloride exhibits linear pharmacokinetic properties. Although it is metabolized by CYP3A and has a high protein binding rate, it carries a low risk of cognitive impairment. Tiagabine hydrochloride is widely used in research on related diseases including epilepsy (including refractory partial seizures), alcohol withdrawal symptoms, and Huntington's disease .
|
-
- HY-B0379AR
-
|
|
Reference Standards
nAChR
|
Neurological Disease
|
|
Adiphenine (hydrochloride) (Standard) is the analytical standard of Adiphenine (hydrochloride). This product is intended for research and analytical applications. Adiphenine hydrochloride is a non-competitive inhibitor of nicotinic acetylcholine receptor (nAChR), with an IC50s of 1.9, 1.8, 3.7, and 6.3 μM for α1, α3β4, α4β2, and α4β4, respectively. Adiphenine hydrochloride has anticonvulsant effects .
|
-
- HY-154736
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N3-(Butyn-3-yl)uridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents . N3-(Butyn-3-yl)uridine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-103566A
-
|
|
mGluR
EGFR
p38 MAPK
Apoptosis
|
Neurological Disease
|
|
LY456236 free base is a selective, non-competitive and orally active antagonist of glutamate receptor 1 (mGlu1), which can inhibit phosphatidylinositol hydrolysis with an IC50 of 0.145 μM. LY456236 free base can also inhibit EGFR, with an IC50 of 0.918 μM. LY456236 free base blocks cell proliferation by inhibiting the MAPK pathway, reversing the anti-apoptotic effect of DHPG (HY-12598A). LY456236 free base can be used in epilepsy research .
|
-
- HY-17549
-
|
CRL 40028
|
Adrenergic Receptor
|
Neurological Disease
|
|
Adrafinil (CRL 40028) is an orally active vigilance promoting agent. Adrafinil enhances central noradrenergic transmission, improves spontaneous activity, exploratory behavior, discriminative learning ability and response motivation, but impairs visuospatial working memory. Adrafinil antagonizes Prazosin (HY-B0193)-induced hypoactivity and hypothermia, exerts anticonvulsant effects, and induces sustained enhancement of high-frequency electrocortical activity. Adrafinil can be used for research on decreased alertness and specific cognitive deficits .
|
-
- HY-I0746
-
|
m-Aminobenzoic acid; 3ABA
|
Endogenous Metabolite
|
Neurological Disease
Inflammation/Immunology
|
|
3-Aminobenzoic acid (3-ABA) is an orally active anti-inflammatory agent targeting the tight junction (TJ) regulatory pathways in intestinal epithelial cells. 3-Aminobenzoic acid improves intestinal inflammation by enhancing intestinal barrier integrity and reducing epithelial permeability. It can be used in studies related to improving gut health. Additionally, 3-Aminobenzoic acid analogs can act as γ-aminobutyric acid transaminase (GABA-AT) inhibitors, exhibiting anticonvulsant effects .
|
-
- HY-105056R
-
|
Ro 16-6028 (Standard)
|
Reference Standards
GABA Receptor
|
Neurological Disease
|
|
Bretazenil (Standard) is the analytical standard of Bretazenil (HY-105056). This product is intended for research and analytical applications. Bretazenil (Ro 16-6028) is a partial agonist at the gamma-aminobutyric acid A (GABAA) receptor-linked benzodiazepine site. Bretazenil is potent benzodiazepine examined, exhibiting an IC50 (concentration at which half-maximal inhibition of specific [35S]TBPS binding occurs) of 6.1 nM. Bretazenil shows an EC50 of 10 nM for recombinant α1β1γ2. Anticonvulsant effects .
|
-
- HY-118424
-
|
|
iGluR
|
Neurological Disease
Metabolic Disease
|
|
JNJ-55511118 is a selective TARP γ-8 binding AMPA receptor modulator with oral bioavailability and blood-brain barrier permeability, with a Ki of 26 nM. JNJ-55511118 reduces voluntary intake of sweetened alcohol in male mice. In rodent models, JNJ-55511118 inhibits hippocampal neurotransmission, reduces specific electroencephalogram frequency bands, induces transient hyperlocomotion, impairs learning and memory abilities, and exerts anticonvulsant effects. JNJ-55511118 is applicable to research related to alcohol use disorder and seizures .
|
-
- HY-77650
-
|
4'-Azidouridine
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
4'-C-azidouridine (4'-Azidouridine) is a uridine analogue. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents . 4'-C-Azidouridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-B0237
-
|
DL-Aminoglutethimide
|
Cytochrome P450
|
Neurological Disease
Endocrinology
Cancer
|
|
Aminoglutethimide (DL-Aminoglutethimide) is an orally active anticonvulsant with various endocrine-related side effects. Aminoglutethimide blocks multiple steroid hormone synthesis pathways by inhibiting several cytochrome P-450-dependent hydroxylases, such as aromatase, cholesterol side-chain cleavage enzyme, 11-hydroxylase, and 18-hydroxylase, with IC50 values of 0.3, 3.5, 120, and 20 μM, respectively. Aminoglutethimide reduces cortisol levels. Aminoglutethimide can be used in research on Cushing's syndrome, breast cancer, and other conditions .
|
-
- HY-D0803R
-
|
|
Reference Standards
Apoptosis
VEGFR
PI3K
Akt
|
Infection
Cardiovascular Disease
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Thymoquinone (Standard) is the analytical standard of Thymoquinone. This product is intended for research and analytical applications. Thymoquinone is an orally active natural product isolated from N. sativa Thymoquinone down-regulates the VEGFR2-PI3K-Akt pathway. Thymoquinone has antioxidant, anti-inflammatory, anticancer, antiviral, anticonvulsant, antifungal, antiviral, antiangiogenic activity and hepatoprotective effects. Thymoquinone can be used to study Alzheimer's disease, cancer, cardiovascular disease, infectious disease and inflammation .
|
-
- HY-W001692
-
|
DOV 273547
|
GABA Receptor
|
Neurological Disease
|
|
Ocinaplon (DOV 273547) is an orally active positive allosteric modulator of GABAA receptor, with an EC50 ranging from 3.07 μM (α1β2γ2 subtype) to 10.03 μM (α1β2γ3 subtype). Ocinaplon enhances GABA-stimulated chloride currents across multiple GABAA receptor subtypes, with varying potency between different subtypes. Ocinaplon exerts anxiolytic and anticonvulsant effects, and causes motor impairment at high doses. Ocinaplon can be used for research on generalized anxiety disorder .
|
-
- HY-W677042
-
|
5α-Androst-16-en-3α-ol
|
GABA Receptor
|
Neurological Disease
|
|
α-Androstenol (5α-Androst-16-en-3α-ol) is a steroid pheromone that has been found in boar testes and male axillary sweat. α-Androstenol is also a positive allosteric modulator of GABAA receptors, which enhances GABA-activated currents in primary mouse cerebellar granule cells (EC50 of 0.4 μM). α-Androstenol produces anxiolytic-like, antidepressant-like, and anticonvulsant effects in mice. α-Androstenol can be used for the research of seizures .
|
-
- HY-152985
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
6-Chloro-N1-(trimethylsilylethoxymethyl)pseudouridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents . 3’-Azido-3’-deoxy-4-deoxyuridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-B1302
-
|
|
P-glycoprotein
PARP
Caspase
Apoptosis
Potassium Channel
|
Cardiovascular Disease
Neurological Disease
|
|
Quinidine hydrochloride monohydrate is an orally active antiarrhythmic agent. Quinidine hydrochloride monohydrate reduces the expression level of P-gp, inhibits P-gp-mediated efflux, increases the intracellular accumulation of P-gp substrates, induces PARP cleavage and Caspase-3 activation, and elevates the proportion of Apoptotic cells at the sub-G1 phase. Quinidine hydrochloride monohydrate exerts sustained block and open-channel block effects on IK(f). Quinidine hydrochloride monohydrate alters the urinary metabolic ratio of Amphetamine, modulates the Pentylenetetrazol-induced seizure threshold, and regulates the anticonvulsant effect of Dextromethorphan. Quinidine hydrochloride monohydrate can be used in studies related to uterine sarcoma and seizures .
|
-
- HY-I0746R
-
|
m-Aminobenzoic acid (Standard); 3ABA (Standard)
|
Reference Standards
Endogenous Metabolite
|
Neurological Disease
Inflammation/Immunology
|
|
3-Aminobenzoic acid (Standard) is the analytical standard of 3-Aminobenzoic acid. This product is intended for research and analytical applications. 3-Aminobenzoic acid (3-ABA) is an orally active anti-inflammatory agent targeting the tight junction (TJ) regulatory pathways in intestinal epithelial cells. 3-Aminobenzoic acid improves intestinal inflammation by enhancing intestinal barrier integrity and reducing epithelial permeability. It can be used in studies related to improving gut health. Additionally, 3-Aminobenzoic acid analogs can act as γ-aminobutyric acid transaminase (GABA-AT) inhibitors, exhibiting anticonvulsant effects .
|
-
- HY-103566R
-
|
|
Reference Standards
mGluR
EGFR
p38 MAPK
Apoptosis
|
Infection
Neurological Disease
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
LY456236 (Standard) is the analytical standard of LY456236 (HY-103566). This product is intended for research and analytical applications. LY456236 is a selective, non-competitive and orally active antagonist of glutamate receptor 1 (mGlu1), which can inhibit phosphatidylinositol hydrolysis with an IC50 of 0.145 μM. LY456236 can also inhibit EGFR, with an IC50 of 0.918 μM. LY456236 has anticonvulsant effects and blocks cell proliferation by inhibiting the MAPK pathway, reversing the anti-apoptotic effect of DHPG (HY-12598A). LY456236 can be used in epilepsy research .
|
-
- HY-N1516R
-
|
|
Reference Standards
Apoptosis
|
Cancer
|
|
3-Aminobenzoic acid (Standard) is the analytical standard of 3-Aminobenzoic acid. This product is intended for research and analytical applications. 3-Aminobenzoic acid (3-ABA) is an orally active anti-inflammatory agent targeting the tight junction (TJ) regulatory pathways in intestinal epithelial cells. 3-Aminobenzoic acid improves intestinal inflammation by enhancing intestinal barrier integrity and reducing epithelial permeability. It can be used in studies related to improving gut health. Additionally, 3-Aminobenzoic acid analogs can act as γ-aminobutyric acid transaminase (GABA-AT) inhibitors, exhibiting anticonvulsant effects .
|
-
- HY-W115674
-
|
|
P-glycoprotein
PARP
Caspase
Apoptosis
Potassium Channel
|
Cardiovascular Disease
Neurological Disease
Cancer
|
|
Quinidine hydrochloride is an orally active antiarrhythmic agent. Quinidine hydrochloride reduces the expression level of P-gp, inhibits P-gp-mediated efflux, increases the intracellular accumulation of P-gp substrates, induces PARP cleavage and Caspase-3 activation, and elevates the proportion of Apoptotic cells at the sub-G1 phase. Quinidine hydrochloride exerts sustained block and open-channel block effects on IK(f). Quinidine hydrochloride alters the urinary metabolic ratio of Amphetamine, modulates the Pentylenetetrazol-induced seizure threshold, and regulates the anticonvulsant effect of Dextromethorphan. Quinidine hydrochloride can be used in studies related to uterine sarcoma and seizures .
|
-
- HY-Y0282
-
|
NSC 77384; Sanibrom 40
|
Environmental Pollutants
|
Neurological Disease
|
|
Sodium bromide (NSC 77384; Sanibrom 40) is a GABA-ergic system modulator that crosses the blood-brain barrier, and it effectively reduces and blocks epileptiform discharges. Sodium bromide exerts significant anticonvulsant effects by enhancing GABA-ergic inhibitory functions, such as increasing the amplitude of inhibitory postsynaptic currents and paired-pulse inhibition. Sodium bromide specifically enhances stimulation-induced extracellular alkalosis without affecting baseline pH or subsequent acidosis processes. Sodium bromide exhibits species-specific pharmacokinetic characteristics, competes with chloride ions for renal tubular reabsorption sites, and serves as a marker for extracellular fluid volume. Sodium bromide can be used in the research of epilepsy and related neurological diseases .
|
-
- HY-154590
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’,3’-Di-O-isopropylidene-4’-alpha-C-azidouridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents . 2’,3’-Di-O-isopropylidene-4’-alpha-C-azidouridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-152782
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
4’-Azido-2’-deoxy-2’-fluoro-beta-D-arabinouridine is a uridine analogue. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents . 4’-Azido-2’-deoxy-2’-fluoro-beta-D-arabinouridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-15080
-
|
LY 293606
|
iGluR
|
Cardiovascular Disease
Neurological Disease
|
|
GYKI 53405 is a non-competitive, orally active AMPA receptor antagonist. GYKI 53405 shows no significant binding affinity for GABAA, GABAB or benzodiazepine receptors. GYKI 53405 increases self-grooming behavior, induces wet dog-like shakes, reduces spontaneous activity, produces anxiolytic-like behavior, reverses the anxiogenic effect induced by mCPP, inhibits locomotor activity, suppresses sound-induced and maximal electroshock-induced seizures, prolongs survival in global cerebral ischemia models, and exhibits sustained anticonvulsant effects at doses below the sedation threshold. GYKI 53405 can be used in research related to absence epilepsy, anxiety disorders and global cerebral ischemia .
|
-
- HY-154357
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
4’-alpha-C-Azido-2’,3’-bis(O-t-butyldimethylsilyl)uridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents . 4’-alpha-C-Azido-2’,3’-bis(O-t-butyldimethylsilyl)uridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-W377455
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
5-Fluoro-1-((2R,3S,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione (2',5-difluoro-2'-deoxy-1-arabinosyluracil) is a uridine analogue. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-W013150
-
|
|
GABA Receptor
|
Neurological Disease
|
|
Alpidem, an anxiolytic agent, is an orally active and brain-penetrant GABAA receptor ligand, binds to α1β2γ2 subunit-containing GABAA receptors (IC50 of 17 nM) over α5β2γ2 subunit-containing GABAA receptors (IC50 of >10 μM). Alpidem modulates calcium-induced mitochondrial permeability transition, induces glutathione depletion and hepatocyte necrosis, potentiates TNF-α toxicity, inhibits marble-burying and locomotor activity, enhances stressed rodent feeding behavior, and exerts anticonvulsant effects. Alpidem can be used for the research of anxiety, anxiety disorders, and convulsions .
|
-
- HY-101392
-
Harmane
1 Publications Verification
|
Imidazoline Receptor
Monoamine Oxidase
Adrenergic Receptor
nAChR
GABA Receptor
Opioid Receptor
|
Neurological Disease
Inflammation/Immunology
|
|
Harmane is a benzodiazepine receptor inhibitor (IC50=7 μM), with IC50 values for mACh, Opioid Receptor, MAO-A/B, and α2-adrenergic receptor of 24 μM, 2.8 μM, 0.5 μM, 5 μM, and 18 μM, respectively. Harmane inhibits the I1 imidazoline receptor (IC50 = 30 nM) to reduce blood pressure and has antidepressant, anti-anxiety, anticonvulsant, and analgesic effects. Harmane inhibits dopamine biosynthesis by decreasing tyrosine hydroxylase (TH) activity and enhancing L-DOPA-induced cytotoxicity in PC12 cells. Additionally, Harmane can increase the mutagenic effect induced by 2-acetylaminofluorene (AAF) .
|
-
- HY-W013150R
-
|
|
Reference Standards
GABA Receptor
|
Neurological Disease
|
|
Alpidem (Standard) is the analytical standard of Alpidem (HY-W013150). This product is intended for research and analytical applications. Alpidem, an anxiolytic agent, is an orally active and brain-penetrant GABAA receptor ligand, binds to α1β2γ2 subunit-containing GABAA receptors (IC50 of 17 nM) over α5β2γ2 subunit-containing GABAA receptors (IC50 of >10 μM). Alpidem modulates calcium-induced mitochondrial permeability transition, induces glutathione depletion and hepatocyte necrosis, potentiates TNF-α toxicity, inhibits marble-burying and locomotor activity, enhances stressed rodent feeding behavior, and exerts anticonvulsant effects. Alpidem can be used for the research of anxiety, anxiety disorders, and convulsions.
|
-
- HY-101392A
-
|
|
Imidazoline Receptor
Monoamine Oxidase
Adrenergic Receptor
nAChR
GABA Receptor
Opioid Receptor
|
Neurological Disease
Inflammation/Immunology
|
|
Harmane hydrochloride is a benzodiazepine receptor inhibitor (IC50=7 μM), with IC50 values for mACh, Opioid Receptor, MAO-A/B, and α2-adrenergic receptor of 24 μM, 2.8 μM, 0.5 μM, 5 μM, and 18 μM, respectively. Harmane hydrochloride inhibits the I1 imidazoline receptor (IC50 = 30 nM) to reduce blood pressure and has antidepressant, anti-anxiety, anticonvulsant, and analgesic effects. Harmane hydrochloride inhibits dopamine biosynthesis by decreasing tyrosine hydroxylase (TH) activity and enhancing L-DOPA-induced cytotoxicity in PC12 cells. Additionally, Harmane hydrochloride can increase the mutagenic effect induced by 2-acetylaminofluorene (AAF) .
|
-
- HY-W013150S
-
|
|
Isotope-Labeled Compounds
GABA Receptor
|
Neurological Disease
|
|
Alpidem-d14 is the deuterium labeled Alpidem (HY-W013150) . Alpidem, an anxiolytic agent, is an orally active and brain-penetrant GABAA receptor ligand, binds to α1β2γ2 subunit-containing GABAA receptors (IC50 of 17 nM) over α5β2γ2 subunit-containing GABAA receptors (IC50 of >10 μM). Alpidem modulates calcium-induced mitochondrial permeability transition, induces glutathione depletion and hepatocyte necrosis, potentiates TNF-α toxicity, inhibits marble-burying and locomotor activity, enhances stressed rodent feeding behavior, and exerts anticonvulsant effects. Alpidem can be used for the research of anxiety, anxiety disorders, and convulsions.
|
-
- HY-179142
-
|
|
COX
TNF Receptor
Interleukin Related
|
Neurological Disease
Inflammation/Immunology
|
|
COX-2-IN-60 is a potent, orally active, and selective COX-2 inhibitor with an IC50 of 0.06 μM. COX-2-IN-60 exhibits ~100-fold selectivity over COX-1 (IC50 = 5.93 ). COX-2-IN-60 reduces oxidative stress and neuroinflammatory cytokines, and effectively counteracts epileptogenesis. COX-2-IN-60 exhibits significant anticonvulsant effects and protects against hippocampal injury by suppressing oxidative stress (reducing MDA and NO), pro-inflammatory signaling (reducing TNF-α and IL-6), and glial activationin in the Pilocarpine (HY-B0726A)-induced seizure mouse model. COX-2-IN-60 can be used for the research on neuroinflammatory and epilepsy .
|
-
- HY-W700834
-
|
|
Isotope-Labeled Compounds
|
Neurological Disease
Inflammation/Immunology
|
|
Harman-d3 is deuterium labeled Harmane. Harmane is a benzodiazepine receptor inhibitor (IC50=7 μM), with IC50 values for mACh, Opioid Receptor, MAO-A/B, and α2-adrenergic receptor of 24 μM, 2.8 μM, 0.5 μM, 5 μM, and 18 μM, respectively. Harmane also inhibits haloperidol and serotonin, with IC50 values of 163 μM and 101 μM, respectively. Harmane inhibits the I1 imidazoline receptor (IC50=30 nM) to reduce blood pressure and has antidepressant, anti-anxiety, anticonvulsant, and analgesic effects. Harmane inhibits dopamine biosynthesis by decreasing tyrosine hydroxylase (TH) activity and enhancing L-DOPA-induced cytotoxicity in PC12 cells. Additionally, Harmane can increase the mutagenic effect induced by 2-acetylaminofluorene (AAF) .
|
-
- HY-W777360
-
|
|
Isotope-Labeled Compounds
Adrenergic Receptor
Monoamine Oxidase
nAChR
Opioid Receptor
Imidazoline Receptor
GABA Receptor
|
Neurological Disease
Inflammation/Immunology
|
|
Harman- 13C2, 15N is 13C and 15N labeled Harmane. Harmane is a benzodiazepine receptor inhibitor (IC50=7 μM), with IC50 values for mACh, Opioid Receptor, MAO-A/B, and α2-adrenergic receptor of 24 μM, 2.8 μM, 0.5 μM, 5 μM, and 18 μM, respectively. Harmane also inhibits haloperidol and serotonin, with IC50 values of 163 μM and 101 μM, respectively. Harmane inhibits the I1 imidazoline receptor (IC50=30 nM) to reduce blood pressure and has antidepressant, anti-anxiety, anticonvulsant, and analgesic effects. Harmane inhibits dopamine biosynthesis by decreasing tyrosine hydroxylase (TH) activity and enhancing L-DOPA-induced cytotoxicity in PC12 cells. Additionally, Harmane can increase the mutagenic effect induced by 2-acetylaminofluorene (AAF) .
|
-
- HY-N4267
-
|
|
Calcium Channel
Platelet-activating Factor Receptor (PAFR)
UGT
Leukotriene Receptor
TNF Receptor
PGE synthase
Interleukin Related
|
Cardiovascular Disease
Infection
Inflammation/Immunology
|
|
Yangambin is a PAF receptor antagonist and UGT1A1/UGT1A3 inhibitor, with an IC50 of 29.7 μM and a Ki of 17.1 μM against human UGT1A1, and an IC50 of 56.5 μM and a Ki of 66.8 μM against human UGT1A3. Yangambin blocks PAF-mediated responses, inhibits LTB4-mediated neutrophil infiltration, and suppresses inflammatory events and anaphylactic contraction. Yangambin acts as a central nervous system inhibitor to reduce spontaneous activity, and also exhibits analgesic, anticonvulsant, antileishmanial, vasodilatory and hypotensive effects. Yangambin blocks voltage-gated Ca 2+ channels, reduces the production of NO, TNF-α, IL-6 and PGE2 in cells, increases the production of IL-10, and exerts a protective effect against cardiovascular injury. Yangambin can be used in research related to allergies, cutaneous leishmaniasis, central nervous system diseases and cardiovascular diseases .
|
-
| Cat. No. |
Product Name |
Type |
-
- HY-Y1267
-
|
|
Biochemical Assay Reagents
|
|
Magnesium sulfate is a calcium antagonist and a potent L-type calcium channel inhibitor, as well as a tocolytic. Magnesium sulfate has anti-inflammatory, anticonvulsant, vasodilatory, and neuroprotective effects. Magnesium sulfate can be used in the research of diseases such as preeclampsia/eclampsia .
|
-
- HY-Y1267D
-
|
|
Biochemical Assay Reagents
|
|
Magnesium sulfate, for cell culture is a bioreagent. Magnesium sulfate is a calcium antagonist and a potent L-type calcium channel inhibitor, as well as a tocolytic. Magnesium sulfate has anti-inflammatory, anticonvulsant, vasodilatory, and neuroprotective effects. Magnesium sulfate can be used in the research of diseases such as preeclampsia/eclampsia .
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P1932
-
-
- HY-P1334
-
-
- HY-114883
-
|
L-Homocarnosine
|
GABA Receptor
Endogenous Metabolite
|
Neurological Disease
Inflammation/Immunology
|
|
Homocarnosine is a dipeptide of γ-aminobutyric acid (GABA) and histidine unique to brain. Homocarnosine is an inhibitory neuromodulator synthesized in the neuron from GABA and exhibiting anticonvulsant effects .Homocarnosine has antioxidant and anti-inflammatory actions, prevention of DNA damage, and inhibition of advanced glycation end-product formation .
|
-
- HY-P1334A
-
-
- HY-114883A
-
|
L-Homocarnosine TFA
|
GABA Receptor
Endogenous Metabolite
|
Neurological Disease
|
|
Homocarnosine TFA is a dipeptide of γ-aminobutyric acid (GABA) and histidine unique to brain. Homocarnosine TFA is an inhibitory neuromodulator synthesized in the neuron from GABA and exhibiting anticonvulsant effects . Homocarnosine TFA has antioxidant and anti-inflammatory actions, prevention of DNA damage, and inhibition of advanced glycation end-product formation .
|
-
- HY-P10698
-
|
|
Peptide-Drug Conjugates (PDCs)
LDLR
|
Neurological Disease
|
|
VH-N412 is a vectorized neuropeptide (NT) with good blood-brain barrier permeability. VH-N412 binds to the low-density lipoprotein receptor (LDLR) and neuropeptide receptor 1 (NTSR-1), and acts as a pharmacological-induced hypothermia (PIH) inducer. VH-N412 exhibits anticonvulsant and neuroprotective effects, and can be used in the study of neurological diseases such as epilepsy.
|
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
-
- HY-D0803
-
|
|
Quinones
Classification of Application Fields
Nigella sativa L.
Ranunculaceae
Benzene Quinones
Plants
Inflammation/Immunology
Disease Research Fields
|
Apoptosis
VEGFR
PI3K
Akt
|
|
Thymoquinone is an orally active natural product isolated from N. sativa Thymoquinone down-regulates the VEGFR2-PI3K-Akt pathway. Thymoquinone has antioxidant, anti-inflammatory, anticancer, antiviral, anticonvulsant, antifungal, antiviral, antiangiogenic activity and hepatoprotective effects. Thymoquinone can be used to study Alzheimer's disease, cancer, cardiovascular disease, infectious disease and inflammation .
|
-
-
- HY-101392
-
Harmane
1 Publications Verification
|
Alkaloids
other families
Pyridine Alkaloids
Plants
Indole Alkaloids
Source Classification
|
Imidazoline Receptor
Monoamine Oxidase
Adrenergic Receptor
nAChR
GABA Receptor
Opioid Receptor
|
|
Harmane is a benzodiazepine receptor inhibitor (IC50=7 μM), with IC50 values for mACh, Opioid Receptor, MAO-A/B, and α2-adrenergic receptor of 24 μM, 2.8 μM, 0.5 μM, 5 μM, and 18 μM, respectively. Harmane inhibits the I1 imidazoline receptor (IC50 = 30 nM) to reduce blood pressure and has antidepressant, anti-anxiety, anticonvulsant, and analgesic effects. Harmane inhibits dopamine biosynthesis by decreasing tyrosine hydroxylase (TH) activity and enhancing L-DOPA-induced cytotoxicity in PC12 cells. Additionally, Harmane can increase the mutagenic effect induced by 2-acetylaminofluorene (AAF) .
|
-
-
- HY-N6778
-
-
-
- HY-12882A
-
-
-
- HY-B1302
-
-
-
- HY-N1469
-
-
-
- HY-108964
-
-
-
- HY-B1229
-
-
-
- HY-N8303
-
|
|
Flavonoids
Flavones
Rutaceae
Plants
Citrus reticulata Blanco
Source Classification
|
ERK
PAK
|
|
Gardenin A is an orally active and synthetic PMF analogue with the neurotrophic effect for neurite outgrowth and neuronal differentiation. Gardenin A promotes neuritogenesis via activating MAPK/ERK, PKC, and PKA, but not TrkA, CREB signaling pathways. Gardenin A also has sedative, anxiolytic, antidepressant, and anticonvulsant effects .
|
-
-
- HY-114883
-
-
-
- HY-101392A
-
|
|
Apocynaceae
Alkaloids
Other Alkaloids
Plants
Rauwolfia canescens
Source Classification
|
Imidazoline Receptor
Monoamine Oxidase
Adrenergic Receptor
nAChR
GABA Receptor
Opioid Receptor
|
|
Harmane hydrochloride is a benzodiazepine receptor inhibitor (IC50=7 μM), with IC50 values for mACh, Opioid Receptor, MAO-A/B, and α2-adrenergic receptor of 24 μM, 2.8 μM, 0.5 μM, 5 μM, and 18 μM, respectively. Harmane hydrochloride inhibits the I1 imidazoline receptor (IC50 = 30 nM) to reduce blood pressure and has antidepressant, anti-anxiety, anticonvulsant, and analgesic effects. Harmane hydrochloride inhibits dopamine biosynthesis by decreasing tyrosine hydroxylase (TH) activity and enhancing L-DOPA-induced cytotoxicity in PC12 cells. Additionally, Harmane hydrochloride can increase the mutagenic effect induced by 2-acetylaminofluorene (AAF) .
|
-
-
- HY-114883A
-
-
-
- HY-N4267
-
|
|
Cardiovascular Disease
Structural Classification
other families
Classification of Application Fields
Lignans
Phenylpropanoids
Plants
Disease Research Fields
Source Classification
|
Calcium Channel
Platelet-activating Factor Receptor (PAFR)
UGT
Leukotriene Receptor
TNF Receptor
PGE synthase
Interleukin Related
|
|
Yangambin is a PAF receptor antagonist and UGT1A1/UGT1A3 inhibitor, with an IC50 of 29.7 μM and a Ki of 17.1 μM against human UGT1A1, and an IC50 of 56.5 μM and a Ki of 66.8 μM against human UGT1A3. Yangambin blocks PAF-mediated responses, inhibits LTB4-mediated neutrophil infiltration, and suppresses inflammatory events and anaphylactic contraction. Yangambin acts as a central nervous system inhibitor to reduce spontaneous activity, and also exhibits analgesic, anticonvulsant, antileishmanial, vasodilatory and hypotensive effects. Yangambin blocks voltage-gated Ca 2+ channels, reduces the production of NO, TNF-α, IL-6 and PGE2 in cells, increases the production of IL-10, and exerts a protective effect against cardiovascular injury. Yangambin can be used in research related to allergies, cutaneous leishmaniasis, central nervous system diseases and cardiovascular diseases .
|
-
-
- HY-D0803R
-
|
|
Quinones
Structural Classification
Nigella sativa L.
Ranunculaceae
Benzene Quinones
Plants
|
Reference Standards
Apoptosis
VEGFR
PI3K
Akt
|
|
Thymoquinone (Standard) is the analytical standard of Thymoquinone. This product is intended for research and analytical applications. Thymoquinone is an orally active natural product isolated from N. sativa Thymoquinone down-regulates the VEGFR2-PI3K-Akt pathway. Thymoquinone has antioxidant, anti-inflammatory, anticancer, antiviral, anticonvulsant, antifungal, antiviral, antiangiogenic activity and hepatoprotective effects. Thymoquinone can be used to study Alzheimer's disease, cancer, cardiovascular disease, infectious disease and inflammation .
|
-
-
- HY-N9502R
-
-
-
- HY-108964R
-
-
-
- HY-N1516R
-
-
-
- HY-N16538
-
-
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-108506S2
-
|
|
|
Licarbazepine-d4-1 is deuterium labeled Licarbazepine. Licarbazepine (BIA 2-005; GP 47779)?is a?voltage-gated sodium channel?blocker?with?anticonvulsant?and?mood-stabilizing?effects .
|
-
-
- HY-B0114S
-
|
|
|
Oxcarbazepine-d4 (GP 47680-D4) is the deuterium labeled Oxcarbazepine. Oxcarbazepine is a sodium channel blocker . Oxcarbazepine significantly inhibits glioblastoma cell growth and induces apoptosis or G2/M arrest in glioblastoma cell lines . Anti-cancer and anticonvulsant effects .
|
-
-
- HY-108506S1
-
|
|
|
Licarbazepine-d4 is the deuterium labeled Licarbazepine (HY-108506). Licarbazepine is a voltage-gated sodium channel blocker with anticonvulsant and mood-stabilizing effects .
|
-
-
- HY-108506S
-
|
|
|
Licarbazepine-d3 is the deuterium labeled Licarbazepine (HY-108506). Licarbazepine is a voltage-gated sodium channel blocker with anticonvulsant and mood-stabilizing effects .
|
-
-
- HY-108506S4
-
|
|
|
Licarbazepine-d8 (BIA 2-005-d8) is deuterium labeled Licarbazepine. Licarbazepine (BIA 2-005; GP 47779)?is a?voltage-gated sodium channel?blocker?with?anticonvulsant?and?mood-stabilizing?effects .
|
-
-
- HY-B0114S1
-
|
|
|
Oxcarbazepine-d4-1 is deuterium labeled Oxcarbazepine. Oxcarbazepine is a sodium channel blocker . Oxcarbazepine significantly inhibits glioblastoma cell growth and induces apoptosis or G2/M arrest in glioblastoma cell lines . Anti-cancer and anticonvulsant effects .
|
-
-
- HY-B0114S3
-
|
|
|
Oxcarbazepine-d10 (GP 47680-d10) is deuterium labeled Oxcarbazepine. Oxcarbazepine is a sodium channel blocker . Oxcarbazepine significantly inhibits glioblastoma cell growth and induces apoptosis or G2/M arrest in glioblastoma cell lines . Anti-cancer and anticonvulsant effects .
|
-
-
- HY-B0114S2
-
|
|
|
Oxcarbazepine-d8-1 is a deuterium of Oxcarbazepine. Oxcarbazepine is a sodium channel blocker . Oxcarbazepine significantly inhibits glioblastoma cell growth and induces apoptosis or G2/M arrest in glioblastoma cell lines . Oxcarbazepine-d8-1 has anti-cancer and anticonvulsant effects .
|
-
-
- HY-A0042S
-
|
|
|
Rufinamide-d2 (CGP 33101-d2) is the deuterium labeled Rufinamide (HY-A0042). Rufinamide (CGP 33101) is an orally active antiepileptic compound that inhibits Na + current activation, inhibits neuronal hyperexcitability, and has anticonvulsant effects. Rufinamide is used in the study of Lennox-Gastaut syndrome .
|
-
-
- HY-W012481S
-
|
|
|
Nirvanol-d5 (Ethylphenylhydantoin-d5) is deuterium labeled Nirvanol (HY-W012481) . Nirvanol (Ethylphenylhydantoin) is a metabolite of Mephenytoin (HY-B1184) that exerts anticonvulsant effects in the maximal electroshock (M.E.S.) seizure model in mice. Nirvanol shows potential for research in epilepsy-related neurological disorders .
|
-
-
- HY-B1283S
-
|
|
|
Mephenesin-d3 is deuterium labeled Mephenesin. Mephenesin is an NMDA receptor antagonist. Mephenesin is also a central muscle relaxant with antianxiety, muscle-paralyzing and anticonvulsant effects. Mephenesin acts directly on the skeletal muscle fibres to produce skeletal muscle relaxation. Mephenesin is promising for research of spasticity or painful muscle spasm .
|
-
-
- HY-A0042S1
-
|
|
|
Rufinamide- 15N,d2 (CGP 33101- 15N,d2) is the deuterium and 15N labeled Rufinamide (HY-A0042).Rufinamide (CGP 33101) is an orally active antiepileptic compound that inhibits Na + current activation, inhibits neuronal hyperexcitability, and has anticonvulsant effects. Rufinamide is used in the study of Lennox-Gastaut syndrome .
|
-
-
- HY-A0042S2
-
|
|
|
Rufinamide- 15N,d2-1 (CGP 33101- 15N,d2-1) is 15N- and deuterium-labeled Rufinamide (HY-A0042).Rufinamide (CGP 33101) is an orally active antiepileptic compound that inhibits Na + current activation, inhibits neuronal hyperexcitability, and has anticonvulsant effects. Rufinamide is used in the study of Lennox-Gastaut syndrome .
|
-
-
- HY-B0696S
-
|
|
|
Tiagabine-d6 (NO050328-d6) is deuterium labeled Tiagabine. Tiagabine (NO050328; NO328; TGB) is an orally active, highly selective, and reversible GAT-1 inhibitor and anticonvulsant that crosses the blood-brain barrier. By blocking the reuptake of GABA in neurons and glial cells, tiagabine increases extracellular GABA levels to enhance inhibitory signal transduction, thereby exerting multiple activities such as anticonvulsant, neuroprotective, and antioxidant effects. Tiagabine exhibits linear pharmacokinetic properties. Although it is metabolized by CYP3A and has a high protein binding rate, it carries a low risk of cognitive impairment. Tiagabine is widely used in research on related diseases including epilepsy (including refractory partial seizures), alcohol withdrawal symptoms, and Huntington's disease .
|
-
-
- HY-B0696AS
-
|
|
|
Tiagabine-d4 hydrochloride is deuterated labeled Tiagabine hydrochloride (HY-B0696A). Tiagabine hydrochloride (NO050328; NO328; TGB) is an orally active, highly selective, and reversible GAT-1 inhibitor and anticonvulsant that crosses the blood-brain barrier. By blocking the reuptake of GABA in neurons and glial cells, tiagabine increases extracellular GABA levels to enhance inhibitory signal transduction, thereby exerting multiple activities such as anticonvulsant, neuroprotective, and antioxidant effects. Tiagabine hydrochloride exhibits linear pharmacokinetic properties. Although it is metabolized by CYP3A and has a high protein binding rate, it carries a low risk of cognitive impairment. Tiagabine hydrochloride is widely used in research on related diseases including epilepsy (including refractory partial seizures), alcohol withdrawal symptoms, and Huntington's disease .
|
-
-
- HY-W013150S
-
|
|
|
Alpidem-d14 is the deuterium labeled Alpidem (HY-W013150) . Alpidem, an anxiolytic agent, is an orally active and brain-penetrant GABAA receptor ligand, binds to α1β2γ2 subunit-containing GABAA receptors (IC50 of 17 nM) over α5β2γ2 subunit-containing GABAA receptors (IC50 of >10 μM). Alpidem modulates calcium-induced mitochondrial permeability transition, induces glutathione depletion and hepatocyte necrosis, potentiates TNF-α toxicity, inhibits marble-burying and locomotor activity, enhances stressed rodent feeding behavior, and exerts anticonvulsant effects. Alpidem can be used for the research of anxiety, anxiety disorders, and convulsions.
|
-
-
- HY-W777360
-
|
|
|
Harman- 13C2, 15N is 13C and 15N labeled Harmane. Harmane is a benzodiazepine receptor inhibitor (IC50=7 μM), with IC50 values for mACh, Opioid Receptor, MAO-A/B, and α2-adrenergic receptor of 24 μM, 2.8 μM, 0.5 μM, 5 μM, and 18 μM, respectively. Harmane also inhibits haloperidol and serotonin, with IC50 values of 163 μM and 101 μM, respectively. Harmane inhibits the I1 imidazoline receptor (IC50=30 nM) to reduce blood pressure and has antidepressant, anti-anxiety, anticonvulsant, and analgesic effects. Harmane inhibits dopamine biosynthesis by decreasing tyrosine hydroxylase (TH) activity and enhancing L-DOPA-induced cytotoxicity in PC12 cells. Additionally, Harmane can increase the mutagenic effect induced by 2-acetylaminofluorene (AAF) .
|
-
-
- HY-158252S
-
|
|
|
Tiagabine-d5 (hydrochloride) is deuterium labeled Tiagabine (hydrochloride). Tiagabine hydrochloride (NO050328; NO328; TGB) is an orally active, highly selective, and reversible GAT-1 inhibitor and anticonvulsant that crosses the blood-brain barrier. By blocking the reuptake of GABA in neurons and glial cells, tiagabine increases extracellular GABA levels to enhance inhibitory signal transduction, thereby exerting multiple activities such as anticonvulsant, neuroprotective, and antioxidant effects. Tiagabine hydrochloride exhibits linear pharmacokinetic properties. Although it is metabolized by CYP3A and has a high protein binding rate, it carries a low risk of cognitive impairment. Tiagabine hydrochloride is widely used in research on related diseases including epilepsy (including refractory partial seizures), alcohol withdrawal symptoms, and Huntington's disease .
|
-
-
- HY-B0696S1
-
|
|
|
Tiagabine-d4 (NO050328-d4) is deuterium labeled Tiagabine. Tiagabine (NO050328; NO328; TGB) is an orally active, highly selective, and reversible GAT-1 inhibitor and anticonvulsant that crosses the blood-brain barrier. By blocking the reuptake of GABA in neurons and glial cells, tiagabine increases extracellular GABA levels to enhance inhibitory signal transduction, thereby exerting multiple activities such as anticonvulsant, neuroprotective, and antioxidant effects. Tiagabine exhibits linear pharmacokinetic properties. Although it is metabolized by CYP3A and has a high protein binding rate, it carries a low risk of cognitive impairment. Tiagabine is widely used in research on related diseases including epilepsy (including refractory partial seizures), alcohol withdrawal symptoms, and Huntington's disease .
|
-
-
- HY-W700834
-
|
|
|
Harman-d3 is deuterium labeled Harmane. Harmane is a benzodiazepine receptor inhibitor (IC50=7 μM), with IC50 values for mACh, Opioid Receptor, MAO-A/B, and α2-adrenergic receptor of 24 μM, 2.8 μM, 0.5 μM, 5 μM, and 18 μM, respectively. Harmane also inhibits haloperidol and serotonin, with IC50 values of 163 μM and 101 μM, respectively. Harmane inhibits the I1 imidazoline receptor (IC50=30 nM) to reduce blood pressure and has antidepressant, anti-anxiety, anticonvulsant, and analgesic effects. Harmane inhibits dopamine biosynthesis by decreasing tyrosine hydroxylase (TH) activity and enhancing L-DOPA-induced cytotoxicity in PC12 cells. Additionally, Harmane can increase the mutagenic effect induced by 2-acetylaminofluorene (AAF) .
|
-
| Cat. No. |
Product Name |
|
Classification |
-
- HY-152782
-
|
|
|
Azide
|
|
4’-Azido-2’-deoxy-2’-fluoro-beta-D-arabinouridine is a uridine analogue. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents . 4’-Azido-2’-deoxy-2’-fluoro-beta-D-arabinouridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-152476
-
|
|
|
Alkynes
|
|
3’-β-C-Ethynyluridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents . 3’-β-C-Ethynyluridine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-154736
-
|
|
|
Alkynes
|
|
N3-(Butyn-3-yl)uridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents . N3-(Butyn-3-yl)uridine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-152985
-
|
|
|
Azide
|
|
6-Chloro-N1-(trimethylsilylethoxymethyl)pseudouridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents . 3’-Azido-3’-deoxy-4-deoxyuridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-154590
-
|
|
|
Azide
|
|
2’,3’-Di-O-isopropylidene-4’-alpha-C-azidouridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents . 2’,3’-Di-O-isopropylidene-4’-alpha-C-azidouridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-154357
-
|
|
|
Azide
|
|
4’-alpha-C-Azido-2’,3’-bis(O-t-butyldimethylsilyl)uridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents . 4’-alpha-C-Azido-2’,3’-bis(O-t-butyldimethylsilyl)uridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
| Cat. No. |
Product Name |
|
Classification |
-
- HY-152358
-
|
|
|
Nucleoside Analogs
Uridine
|
|
N3-Methyl-2’-O-methyluridine is a uridine analogue. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-134337
-
|
|
|
Phosphoramidites
Uracil
|
|
5'-O-DMTr-3'-O-methyl uridine-3'-CED-phosphoramidite is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-152732
-
|
|
|
Nucleoside Analogs
Uridine
|
|
6-Methyluridine is a uridine analogue. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-154285
-
|
|
|
Nucleoside Analogs
Uridine
|
|
3’-O-(2-Methoxyethyl) uridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-154466
-
|
|
|
Nucleoside Analogs
Uridine
|
|
5’-O-(4,4’-Dimethoxytrityl)-3’-O-methyluridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-48973
-
|
|
|
Phosphoramidites
Uracil
|
|
2'-Fluoro-2'-deoxy-ara-U-3'-phosphoramidite is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-154358
-
|
|
|
Nucleoside Analogs
Uridine
|
|
4’-alpha-C-Allyl-2’,3’-bis(O-t-butyldimethylsilyl) uridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-154492
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2’,3’-Bis(O-t-butyldimethylsilyl)-4’,5’-didehydro-5’-deoxyuridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-154582
-
|
|
|
Nucleoside Analogs
Uridine
|
|
5-Naphthyl-beta-methylaminocarbony-3’-O-acetyl-2’-O-methyl-5’-O-DMTr-uridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-152782
-
|
|
|
Nucleoside Analogs
Uridine
|
|
4’-Azido-2’-deoxy-2’-fluoro-beta-D-arabinouridine is a uridine analogue. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents . 4’-Azido-2’-deoxy-2’-fluoro-beta-D-arabinouridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-W020098
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2'-C-methyluridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-154488
-
|
|
|
Nucleoside Analogs
Uridine
|
|
3′-O-[(1,1-Dimethylethyl)dimethylsilyl]-2′-O-methyluridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-154517
-
|
|
|
Nucleoside Analogs
Uridine
|
|
N3-Cyanoethyl-5’-O-(4,4’-dimethoxytrityl)-2’-O-methyluridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-152755
-
|
|
|
Nucleoside Analogs
Uridine
|
|
4’-Cyanouridine is a uridine analogue. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-152764
-
|
|
|
Nucleoside Analogs
Uridine
|
|
4’-α-C-Methyluridine is a uridine analogue. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-152777
-
|
|
|
Nucleoside Analogs
Uridine
|
|
5’(R)-C-Methyluridine is a uridine analogue. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-152299
-
|
|
|
Nucleoside Analogs
Uridine
|
|
5-(t-Butyloxycarbonylmethoxy)uridine is a uridine analogue. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-154735
-
|
|
|
Nucleoside Analogs
Uridine
|
|
N3-Allyluridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-152388
-
|
|
|
Nucleoside Analogs
Uridine
|
|
3’-beta-C-Methyluridine is a uridine analogue. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-152665
-
|
|
|
Nucleoside Analogs
Uridine
|
|
1-(β-D-Xylofuranosyl)uracil is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-152970
-
|
|
|
Phosphoramidites
Uracil
|
|
7'-O-DMT-morpholino uracil is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-154734
-
|
|
|
Nucleoside Analogs
Uridine
|
|
N3-(4-Nitrobenzyl)uridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-W557556
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2',5'-Bis-O-(triphenylMethyl)uridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-152677
-
|
|
|
Nucleoside Analogs
Uridine
|
|
N3-(2-Methoxy)ethyluridine is a uridine analogue. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-154217
-
|
|
|
Nucleoside Analogs
Uridine
|
|
3′,5′-Bis-O-(triphenylmethyl)uridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-152529
-
|
|
|
Nucleoside Analogs
Uridine
|
|
4’-C-Methyl-5-methoxyuridine is a uridine analogue. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-152522
-
|
|
|
Nucleoside Analogs
Uridine
|
|
5-Fluoro-4’-C-methyluridine is a uridine analogue. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-154738
-
|
|
|
Nucleoside Analogs
Uridine
|
|
N3-[3-(tert-Butoxycarbonyl)amino]propyluridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-152783
-
|
|
|
Nucleoside Analogs
Uridine
|
|
5’(R)-C-Methyl-5-fluorouridine is a uridine analogue. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-152969
-
|
|
|
Nucleoside Analogs
Uridine
|
|
6-Chloro-N1-(trimethylsilylethoxymethyl)pseudouridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-152779
-
|
|
|
Nucleoside Analogs
Uridine
|
|
5-Methoxy-5’(R)-C-methyluridine is a uridine analogue. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-152798
-
|
|
|
Nucleoside Analogs
Uridine
|
|
5-Iodo-2’-β-C-methyl uridine is a uridine analogue. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-154737
-
|
|
|
Nucleoside Analogs
Uridine
|
|
N3-[(Pyrid-4-yl)methyl]uridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-152681
-
|
|
|
Nucleoside Analogs
Uridine
|
|
N3-[(Tetrahydro-2-furanyl)methyl]uridine is a uridine analogue. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-152463
-
|
|
|
Nucleoside Analogs
Uridine
|
|
4′-C-2-Propen-1-yluridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-152683
-
|
|
|
Nucleoside Analogs
Uridine
|
|
N3-[(Pyrid-2-yl)methyl]uridine is a uridine analogue. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-152574
-
|
|
|
Nucleoside Analogs
Uridine
|
|
5-Amino-2’-deoxy-2’-O-methyluridine hydrochloride is a uridine analogue. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-152674
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2′-Deoxy-2′-fluoro-5-methoxy-arabinouridine is a uridine analogue. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-154560
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2’,3’,5’-Tri-O-acetyl-N3-methyluridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-152363
-
|
|
|
Nucleoside Analogs
Uridine
|
|
N3-Methyl-2’-O-(2-methoxyethyl)uridine is a uridine analogue. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-154173
-
|
|
|
Nucleoside Analogs
Uridine
|
|
3’-O-(t-Butyldimethylsilyl)-2’-O-(2-methoxyethyl) uridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-154813
-
|
|
|
Nucleoside Analogs
Uridine
|
|
3′,5′-Di-O-acetyl-2′-deoxy-2′-fluorouridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-49199
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2',3',5'-Tri-O-(t-butyldimethylsilyl)-4'-C-hydroxymethyl uridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-154410
-
|
|
|
Phosphoramidites
Uracil
|
|
5’-O-DMT-2’-deoxy-2’-fluoro-β-D-arabinouridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-152691
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2’-Deoxy-2’-fluoro-N3-(n-dodecyl)-beta-D-arabinouridine is a uridine analogue. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-154175
-
|
|
|
Nucleoside Analogs
Uridine
|
|
1-[6-(Diethoxyphosphinyl)-2-O-(2-methoxyethyl)-β-D-ribo-hexofuranosyl]uracil is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-152792
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2’-Deoxy-2’-fluoro-N3-[(pyrid-2-yl)methyl]uridine is a uridine analogue. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-154552
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2’-O-Acetyl-5’-O-benzoyl-3’-O-(2-methoxyethyl) uridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-154647
-
|
|
|
Nucleoside Analogs
Uridine
|
|
N3-(2S)-[2-(tert-Butoxycarbonyl)amino-3-(tert-butoxy carbonyl)]propyluridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
-
- HY-154652
-
|
|
|
Nucleoside Analogs
|
|
1-(2,3,5-Tri-O-benzoyl-2-C-methyl-β-D-ribofuranosyl)-2,4(1H,3H)-pyrimidinedione is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents .
|
- HY-152476
-
|
|
|
Nucleoside Analogs
Uridine
|
|
3’-β-C-Ethynyluridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents . 3’-β-C-Ethynyluridine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
- HY-154736
-
|
|
|
Nucleoside Analogs
Uridine
|
|
N3-(Butyn-3-yl)uridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents . N3-(Butyn-3-yl)uridine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
- HY-77650
-
|
4'-Azidouridine
|
|
Nucleoside Analogs
Uridine
|
|
4'-C-azidouridine (4'-Azidouridine) is a uridine analogue. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents . 4'-C-Azidouridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
- HY-152985
-
|
|
|
Nucleoside Analogs
Uridine
|
|
6-Chloro-N1-(trimethylsilylethoxymethyl)pseudouridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents . 3’-Azido-3’-deoxy-4-deoxyuridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
- HY-154590
-
|
|
|
Nucleoside Analogs
Uridine
|
|
2’,3’-Di-O-isopropylidene-4’-alpha-C-azidouridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents . 2’,3’-Di-O-isopropylidene-4’-alpha-C-azidouridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
- HY-154357
-
|
|
|
Nucleoside Analogs
Uridine
|
|
4’-alpha-C-Azido-2’,3’-bis(O-t-butyldimethylsilyl)uridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents . 4’-alpha-C-Azido-2’,3’-bis(O-t-butyldimethylsilyl)uridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: